Corixa Corp. said it is requesting an appeal of the FDA's complete review letter questioning the net clinical benefit and safety of the company's lead cancer product, known as Bexxar. (BioWorld Today)
Corixa Corp. said it is requesting an appeal of the FDA's complete review letter questioning the net clinical benefit and safety of the company's lead cancer product, known as Bexxar. (BioWorld Today)
The FDA is not expected to grant ViroPharma Inc. regulatory clearance for its cold medicine that has been criticized for reducing the duration of illness by only one day. (BioWorld Today)
The FDA is not expected to grant ViroPharma Inc. regulatory clearance for its cold medicine that has been criticized for reducing the duration of illness by only one day. (BioWorld Today)
WASHINGTON - President Bush's choice as director of the National Institutes of Health won Senate confirmation, just in time to enter the pending debate on Capitol Hill concerning therapeutic cloning. (BioWorld Today)
WASHINGTON - President Bush's choice as director of the National Institutes of Health won Senate confirmation, just in time to enter the pending debate on Capitol Hill concerning therapeutic cloning. (BioWorld Today)
Amgen Inc. said it will pay Roche Holding AG $137.5 million to gain control over European assets and business related to two white-cell boosters that are sold in the U.S. under the names Neupogen and Neulasta. (BioWorld Today)
